Page 8 of 13: studies 141 to 160 of 255, newest first. Back to the esketamine overview
Journal of Pre-Clinical and Clinical Research May 12, 2026 Bartłomiej Kosiarski, A. Skrzypek, Patrycja Markowicz et al.
Rapid-acting interventions in treatment-resistant depression – a comparative review of
Psychiatry Research May 12, 2026 Isis Lunsky, Gilmar Gutierrez, Xena Wang et al.
Postpartum Depression (PPD) is a common condition with serious consequences for both mother and baby if left untreated. Currently, few effective strategies exist for prevention of PPD. Ketamine and Esketamine are rapid acting and potent antidepressants, and emerging evidence is showing promising results for PPD. This review searched the MEDLINE, CINAHL, PsycINFO, EMBASE, and Cochrane databases,...
The Journal of Clinical Psychiatry May 4, 2026 Samuel T. Wilkinson, Brandon Kitay, Matthew Macaluso et al.
Background: Suicide is a public health crisis in the US, with limited evidence demonstrating efficacy of treatments for high-risk patients due in part to their exclusion from most clinical trials. This clinical trial evaluates the feasibility and efficacy of adjunctive cognitive behavioral therapy (CBT) with esketamine in patients with major depression and suicidal ideation (MDSI). Methods:...
The International Journal of Neuropsychopharmacology May 3, 2026 Mostafa El Mansari, Naomichi Okamoto, Pierre Blier
Abstract Background In preclinical studies, an increase in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) to N-methyl-D-aspartate (NMDA) receptor throughput is the predominant hypothesis posited to explain the rapid antidepressant effect of ketamine and S-ketamine. Several lines of evidence show that this AMPA increase takes place in the medial prefrontal cortex (mPFC), which...
Journal of Biochemical and Molecular Toxicology May 1, 2026 Jingyi Wang, Shuo Huang, Tingting Lin et al.
Esketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, has become a preferred option for perioperative use in infants and young children with low compliance due to its rapid onset and convenient administration. However, concerns regarding its potential neurotoxic effects during development warrant further investigation. This study aimed to elucidate the impact of esketamine on...
CNS Neuroscience & Therapeutics May 1, 2026 Xuewei Qin, Xuanling Chen, Lan Yao et al.
BACKGROUND: Disorders of consciousness (DoC) present significant therapeutic challenges with limited effective interventions. The choice of anesthetic agent during procedures such as spinal cord stimulation may influence long-term neurological outcomes, yet comparative evidence is scarce. This prospective, non-randomized, comparative effectiveness trial investigated the neurophysiological and...
Journal of Affective Disorders May 1, 2026 Michel Danon, Gabriela Ostronoff, Anne-Cécile Petit et al.
Regulatory approvals for intranasal esketamine in treatment-resistant depression (TRD) differ with respect to its indication for suicidal ideation. While rapid antidepressant effects are well documented, whether esketamine exerts an anti-suicidal effect independent of mood improvement remains unclear. In this two-center observational study, 261 adults with moderate-to-severe TRD at Sainte-Anne...
Medicine May 1, 2026 Hai-Lin Hu, Qi-Zhou Huang, Ping-Xia Xie
Esketamine, the S-enantiomer of ketamine, has emerged as a rapid-acting antidepressant with unique mechanisms. This narrative review synthesizes current evidence on its clinical applications, safety, and regulatory status based on peer-reviewed literature published between January 2000 and March 2024, searched in PubMed, Web of Science, and the Cochrane Library. Esketamine exerts its effects...
Journal of Clinical Psychopharmacology May 1, 2026 Matteo Carminati, Mattia Tondello, Chiara Morana et al.
Growing evidence links inflammation with major depressive disorder (MDD) and treatment resistance. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a simple peripheral marker of systemic inflammation and immune balance and it may capture clinically meaningful heterogeneity in inflammatory burden, potentially contributing to variability in antidepressant response and vulnerability to...
Cureus May 1, 2026 Amalesh S Honnekeri
Treatment-resistant depression (TRD) remains a significant clinical concern, particularly in patients who do not achieve adequate response with conventional antidepressant therapies. Ketamine and esketamine, which act on glutamatergic pathways, have been introduced into clinical practice as alternative therapeutic approaches within interventional psychiatry. This narrative review outlines key...
International Journal of Psychiatry in Clinical Practice April 29, 2026 David Eckert, Siegfried Kasper
The treatment of treatment-resistant depression (TRD) remains a clinical challenge. Pharmacologically, several augmentation options exist. The aim of this study was to present a mechanistically informed and clinically oriented decision-making framework for the established strategies of lithium, quetiapine, and esketamine. We conducted a narrative, non-systematic review, performing a targeted...
BMC Psychiatry April 26, 2026 Sergi López-rodríguez, Cinto Segalàs, Eva Real et al.
BACKGROUND: Patients with obsessive–compulsive disorder (OCD) and comorbid major depressive disorder (MDD) represent a severe subgroup with increased treatment resistance, greater functional impairment, and limited therapeutic options. Intranasal esketamine is a rapidly acting treatment for resistant depression, with emerging interest in potential anti-obsessional effects. However, prospective...
The pharmacogenomics journal April 24, 2026 Daniël T Coerts, Sanne Y Smith-Apeldoorn, Jérôme C Oude Nijhuis et al.
Oral esketamine displays therapeutic potential for treatment-resistant depression. However, treatment is complicated by a low and variable bioavailability. Genetic polymorphisms in the cytochrome P450 (CYP) enzymes responsible for esketamine's metabolism may influence bioavailability. In a subsample of patients included in a placebo-controlled trial investigating repeated, low dose oral...
Journal of Psychopharmacology April 24, 2026 Marco Colizzi, Elisa Morandin, Veronica Croccia et al.
Interleukin-6 (IL-6) has been implicated as a potential predictor of ketamine response in treatment-resistant depression (TRD). Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects and offers improved safety and intranasal administration. To examine whether baseline IL-6 predicts treatment response to esketamine in individuals with TRD. Fourteen adults with TRD...
Frontiers in Neurology April 23, 2026 Jing Cao, ZiYuan Wang, GeGe Lv et al.
Background Paclitaxel (PTX), a broad-spectrum anti-tumor drug, is extensively employed as a first-line chemotherapy for solid tumors, including lung and breast cancers. However, it induces chemotherapy-related pain and anxiety in over 53% of patients. S-ketamine, the S-enantiomer of ketamine, exerts rapid antidepressant effects. In this study, we established a PTX model to examine the effects...
April 21, 2026 Samuel T. Wilkinson
Reserveer ketamine of esketamine voor patiënten bij wie twee tot vier adequate antidepressieve behandelingen onvoldoende effect hebben gehad. Weeg ook de ernst mee; bij milde gevallen is dit doorgaans niet geïndiceerd. Overweeg esketamine bij acute suïcidaliteit bij therapieresistente depressie, ondanks de negatieve studieresultaten. De placebogroepen ontvingen uitstekende intramurale...
April 21, 2026 Samuel T. Wilkinson
Wanneer een patiënt terugvalt na het afbouwen van ketamine of esketamine, overweeg dan een herstart van een inductiekuur (tweemaal per week gedurende enkele weken, vervolgens geleidelijk spreiden). Bij ketamine of esketamine treden dysfore reacties op bij ongeveer 1 op de 200-300 behandelingen. Veel hiervan verdwijnen met ondersteunende zorg alleen; andere vereisen een kortwerkend...
April 21, 2026 Samuel T. Wilkinson
Na het voltooien van deze activiteit dienen deelnemers in staat te zijn om: Geschikte kandidaten voor ketamine of esketamine te identificeren op basis van eerdere behandelmislukkingen, ernst van de aandoening, middelengebruiksgeschiedenis en relevante contra-indicaties. Strategieën te beschrijven voor onderhoudsdosering, afbouw en het omgaan met snelle terugval na het staken van ketamine of...
April 21, 2026 Samuel T. Wilkinson
Reserve ketamine or esketamine for patients who have failed two to four adequate antidepressant trials. Weigh severity too; mild cases may not warrant it. Consider esketamine for acute suicidality in TRD despite the negative trial results. Placebo groups received excellent inpatient standard of care and improved substantially, masking the drug's benefit. Avoid ketamine and esketamine in active...
April 21, 2026 Samuel T. Wilkinson
After completing this activity, participants should be able to: Identify appropriate candidates for ketamine or esketamine based on prior treatment failures, severity, substance use history, and relevant contraindications. Describe strategies for maintenance dosing, tapering, and managing rapid relapse after discontinuation of ketamine or esketamine. Apply clinic-based approaches to managing...